A snapshot of U.S. reproductive rights as of August 24, 2026 shows six notable developments, ranging from maternity care access to legal actions involving the DOJ, court rulings on health-preserving abortions, teen pregnancy program funding, and shifts in federal leadership that could affect abortion policy.

A federal judge in Idaho ruled that the U.S. Constitution protects the right to health-preserving abortions, blocking state criminalization in cases involving serious health risks or high risk of self-harm, while state bans and voter measures loom as potential battles over abortion rights.

A March of Dimes report finds that about one in three counties lack maternity care facilities or obstetric providers, with more than half lacking a hospital with labor and delivery units, contributing to longer travel times for care as states explore expanded midwifery access.

There’s a rising trend in state bills charging abortion patients with homicide (from 3 in 2024 to 14 in 2026), with continued efforts in states like Tennessee amid ongoing debates over abortion pill safety and prevalence.

Sunita Doddamani, a former Assistant U.S. Attorney, has sued the Justice Department claiming she was fired for prosecuting anti-abortion protesters under the FACE Act, highlighting tensions over enforcement and related records on presidential pardons.

A federal judge blocked proposed cuts to a national teen pregnancy prevention program, preserving evidence-based programming such as fertility tracking and reproductive goals counseling, while noting about $70 million in previously canceled funding remains unavailable.

Upcoming events include an Olivia Rodrigo–led festival on August 29 to support reproductive rights donations and September 9 Fifth Circuit hearings on telehealth access to abortion pills, underscoring ongoing debates over medication abortion access via telemedicine.

The political landscape tightens with the Senate’s confirmation of anti-abortion attorney general nominee Todd Blanche and President Trump’s nomination of Heidi Overton to head the FDA, both poised to influence abortion policy and access, including potential actions on mifepristone and the broader regulatory environment.

These developments draw on a range of sources from March of Dimes, the Center for Reproductive Rights, and researchers at Guttmacher Institute, NYT, NPR, and Stateline, reflecting the multifaceted legal, policy, and public health discussion surrounding reproductive rights.